Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



October 2005, Volume 35 Number 10 , p 30 - 30



 Under a new FDA program, everyone prescribing, taking, selling, or dispensing the acne drug isotretinoin (Accutane) will be required to enroll in a national registry by the end of the year. The iPLEDGE program is intended to ensure that health care professionals and patients understand the drug's serious risks—miscarriage, severe birth defects, depression, and suicidal thoughts—and take appropriate precautions, including avoiding pregnancy. Notorious for causing birth defects, isotretinoin has long been under fire by the March of Dimes and other advocacy groups who want it tightly controlled or taken off the market altogether.

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: